Business Wire

NetWitness Announces New Threat Detection and Intelligence Capabilities with NetWitness Platform XDR 12

15.9.2022 02:59:00 EEST | Business Wire | Press release

Share

NetWitness, a globally trusted provider of cybersecurity technologies and incident response, today announced the upcoming availability of NetWitness Platform XDR 12 later this month, the industry’s most comprehensive extended detection and response solution. NetWitness Platform XDR 12 is the first solution on the market to deliver on the promise of extended detection and response.

Developed in response to real-world customer needs, NetWitness Platform XDR 12 is focused on sophisticated detection, which is at the core of effective threat defense. The updated platform offers full visibility into all key data planes across an organization including network, logs, endpoint, and Internet of Things (IoT); full Security Orchestration, Automation, and Response (SOAR); a complete Threat Intelligence Platform (TIP); User and Entity Behavior Analytics (UEBA); and new asset analytics and prioritization, all easily viewed in a single interface and a unified data model.

“Effective security teams need tools that can bring insights together from multiple data sources and deliver comprehensive, actionable alerting,” said Kevin Bowers, Director, Product Management at NetWitness. “Embracing this principle, NetWitness built XDR functionality long before the phrase was popularized. This release delivers the promise of XDR: the ability for security teams to detect attacks across all an organization's information assets and infrastructure, and to stop them before they cause damage.”

The updated NetWitness Platform XDR solution features new and enhanced analytics capabilities that can find known and unknown threats even faster, to reduce dwell time and allow response and remediation before adversaries can successfully execute a harmful attack. NetWitness Platform XDR 12 also makes it easier for users to deploy and manage threat detection content bundles that target specific threat categories, vertical industries, and use cases, providing more effective threat coverage.

NetWitness began as a government-sponsored research project to inspect network packets for cyberthreats and to develop the tools to detect and respond to them. Since then, the technology has continuously evolved in real-world usage to tackle today’s most complex attacks. NetWitness now features fully integrated components for network, log, endpoint and IoT detection and response. With its long history and global footprint, NetWitness Platform XDR integrates directly with the world’s most critical and widely deployed tools, as well as many specialized and industry-specific solutions.

“XDR concepts aren’t new, but they’re incredibly important,” said Bill Hart, Senior Product Manager for NetWitness Platform XDR. “We long ago integrated the primary data planes – network, endpoint, log and IoT – into a unified data model allowing for advanced detection capabilities that are independent of the data source. Others that have recently adopted an XDR strategy still analyze different data types in silos and attempt to correlate at the alert level; this leaves visibility gaps. Sophisticated, multi-vector attack detection requires holistic, data level integration and analysis.”

To learn more about the new NetWitness Platform XDR 12, visit netwitness.com. Additionally, those attending the Black Hat Conference in Las Vegas on August 6-11 are encouraged to stop by the NetWitness booth (2941) for a NetWitness Platform XDR 12 product demo.

About NetWitness

NetWitness, an RSA® Group Business, provides comprehensive and highly scalable threat detection and response capabilities for organizations around the world. The NetWitness Platform delivers complete visibility combined with applied threat intelligence and user behavior analytics to detect, prioritize, investigate threats, and automate response. This empowers security analysts to be more efficient and stay ahead of business-impacting threats. For more information, visit netwitness.com.

©2022 RSA Security LLC or its affiliates. All rights reserved. RSA and the RSA logo are trademarks of RSA Security LLC or its affiliates. For a list of RSA trademarks visit https://www.rsa.com/en-us/company/rsa-trademarks . Other trademarks are trademarks of their respective owners. RSA believes the information in this document is accurate. The information is subject to change without notice.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contact:
SHIFT Communications
netwitness@shiftcomm.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye